Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells

Veterinary Immunology and Immunopathology

Volumn 133, Issue 1, 2010, Pages 9-15

  Cerrato, S ^a   Brazis, P ^a   della Valle, M F ^b   Miolo, A ^b   Puigdemont, A ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Innovet Italia srl   (Italy)

Author keywords

Canine mast cells; Endocannabinoids; Histamine; PGD2; TNF

Indexed keywords

HISTAMINE; IMMUNOGLOBULIN E ANTIBODY; PALMIDROL; PROSTAGLANDIN D2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL ISOLATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DOG; DOG DISEASE; DRUG MECHANISM; DRUG SCREENING; HISTAMINE RELEASE; IMMUNOMODULATION; INFLAMMATORY DISEASE; MAST CELL; NONHUMAN; PROSTAGLANDIN RELEASE; SKIN BIOPSY; SKIN CELL; SKIN DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTI-IDIOTYPIC; DOGS; DOWN-REGULATION; HISTAMINE; MAST CELLS; PALMITIC ACIDS; PROSTAGLANDIN D2; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; CANIS FAMILIARIS;

EID: 71649099454     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2009.06.011     Document Type: Article

References (56)

1. Aloe L., Leon A., and Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 39 Spec. No. C (1993) 145-147
2. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., and Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353 (1998) 23-31
3. Biro T., Maurer M., Modarres S., Lewin N.E., Brodie C., Acs G., Acs P., Paus R., and Blumberg P.M. Characterization of functional vanilloid receptors expressed by mast cells. Blood 91 (1998) 1332-1340
4. Brazis P., Torres R., Queralt M., de Mora F., Ferrer L., and Puigdemont A. Evaluation of cell-surface IgE receptors on the canine mastocytoma cell line C2 maintained in continuous culture. Am. J. Vet. Res. 63 5 (2002) 763-766
5. Brazis P., Queralt M., de Mora F., Ferrer L., and Puigdemont A. Stem cell factor enhances IgE-mediated histamine and TNF-alpha release from dispersed canine cutaneous mast cell. Vet. Immunol. Immunopathol. 75 1-2 (2000) 97-108
6. Calignano A., La Rana G., and Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitoylethanolamide. Eur. J. Pharmacol. 419 2-3 (2001) 191-198
7. Conti S., Costa B., Colleoni M., Parolaro D., and Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol. 135 1 (2002) 181-187
8. Costa B., Comelli F., Bettoni I., Colleoni M.P., and Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1. TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 139 (2008) 541-550
9. D'Agostino G., La Rana G., Russo R., Sasso O., Iacono A., Esposito E., Mattace Raso G., Cuzzocrea S., Lo Verme J., Pomelli D., Meli R., and Malignano A. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous PPAR-{alpha} agonist, modulates carrageenan-induced paw edema in mice. J. Pharmacol. Exp. Ther. 322 (2007) 1137-1143
10. Darmani N.A., Izzo A.A., Degenhardt B., Valenti M., Scaglione G., Papasso F., Sorrentini I., and Di Marzo V. Involvement of the cannabimimetic compound, N-palmitoylethanolamine, in inflammatory and neuropathic conditions. A review of the available pre-clinical data and first human studies. Neuropharmacology 48 (2005) 1154-1163
11. De Filippis D., D'Amico A., and Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J. Neuroendrocrinol. 20 Suppl. 1 (2008) 20-25
12. De Mora F., Puigdemont A., and Torres R. The role of mast cells in atopy: what can we learn from canine models? A thorough review of the biology of mast cells in canine and human systems. Br. J. Dermatol. 155 (2006) 1109-1123
13. De Petrocellis L., Bisogno T., Ligresti A., Bifulco M., Melck D., and Di Marzo V. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam. Clin. Pharmacol. 16 (2002) 297-302
14. Di Marzo V. Biochemistry and pharmacology of fatty acid amides-effects on inflammation, pain and pruritus and new perspectives in veterinary medicine. J. Vet. Pharmacol. Ther. 29 Suppl. 1 (2006) 2-4
15. Eberlein B., Eicke C., Reinhardt H.W., and Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J. Eur. Acad. Dermatol. Venereol. 22 1 (2008) 73-82
16. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., and Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U.S.A. 92 8 (1995) 3376-3380
17. Farquhar-Smith W.P., and Rice A.S. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology 99 (2003) 1391-1401
18. Garcia G., Ferrer L., de Mora F., and Puigdemont A. Inhibition of histamine release from dispersed canine skin mast cells by cyclosporine A, rolipram and salbutamol, but not by dexamethasone or sodium cromoglycate. Vet. Dermatol. 9 (1998) 81-86
19. Galli S.J. The mast cell: a versatile effectors cell for a challenging world. Int. Arch. Allergy Immunol. 113 (1997) 14-22
20. Granberg M., Fowler C.J., and Jacobsson S.O. Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoylethanolamide and methanandamide upon IgE-dependent antigen-induced beta-hexosaminidase, serotonin and TNF alpha release from rat RBL-2H3 basophilic leukaemic cells. Naunyn Schmiedebergs Arch. Pharmacol. 364 1 (2001) 66-73
21. Griffin G., Tao Q., and Abood M.E. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J. Pharmacol. Exp. Ther. 292 (2000) 886-894
22. Gschwandtner M., Purwar R., Wittmann M., Bäumer W., Kietzmann M., Werfel T., and Gutzmer R. Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J. Invest. Dermatol. 128 (2008) 2783-2791
23. Gueck T., Aschenbach J.R., and Fuhrmann H. Influence of vitamin E on mast cell mediator release. Vet. Dermatol. 13 (2002) 301-305
24. Hammerberg B., Olivry T., and Orton S.M. Skin mast cell histamine release following stem cell factor and high-affinity immunoglobulin E receptor cross-linking in dogs with atopic dermatitis. Vet. Dermatol. 12 (2001) 339-346
25. Holgate S.T., Robinson C., and Church M.K. Mediators of immediate hypersensitivity. In: Middleton Jr. (Ed). Allergy: Principles and Practice (1993) St. Louis, pp. 267-301
26. Iuvone T., De Filippis D., D'Amico A., Petrosino S., and Di Marzo V. Protective role of aliamides and endocannabinoid system during lambda-carrageenan-induced granuloma formation. Proceedings 3rd International Conference on "Phospholipase A2 and Lipid Mediators". Sorrento, Italy (2007) 143
27. Jack D.B. Aliamides: a new approach to the treatment of inflammation. Drug News Perspect. 9 (1996) 93-98
28. Jonsson K.O., Persson E., and Fowler C.J. The cannabinoid CB(2) receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of beta-hexosaminidase from skin slices in vitro. Life Sci. 78 (2006) 598-606
29. Kakurai M., Monteforte R., Suto H., Tsai M., Nakae S., and Galli S.J. Mast cell-derived tumor necrosis factor can promote nerve fiber elongation in the skin during contact hypersensitivity in mice. Am. J. Pathol. 169 (2006) 1713-1721
30. Kimura I., Moritani Y., and Tanizaki Y. Basophils in bronchial asthma with reference to reagin-type allergy. Clin. Allergy 3 2 (1979) 195-202
31. Lambert D.M., and Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Curr. Med. Chem. 6 (1999) 757-773
32. Lambert D.M., Vandevoorde S., Jonsson K.O., and Fowler C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents?. Curr. Med. Chem. 9 (2002) 663-674
33. Lau A.H., and Chow S.S. Effects of cannabinoids receptor agonist on immunologically induced histamine release from rat peritoneal mast cells. Eur. J. Pharmacol. 464 (2003) 229-235
34. Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., and Piomelli D. The nuclear receptor PPAR-α mediates the antiinflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67 (2005) 15-19
35. Maeyama K., Emi M., and Tachibana M. Nuclear receptors as targets for drug development: peroxisome proliferator-activated receptor gamma in mast cells: its roles in proliferation and differentiation. J Pharmacol. Sci. 97 (2005) 190-194
36. Marsella R., Joyce J., Nicklin C., and Lopez J. Evaluation of the effects of palmitoylethanolamide on clinical signs in house dust mite allergic high IgE beagle dogs using a randomized, double blinded, placebo controlled design. Vet. Dermatol. 16 (2005) 202 (Abstract from the ACVD/ASVD Congress, 2005, Saratosa, Florida)
37. Mazzari S., Canella R., Petrelli L., Marcolongo G., and Leon A. N-(2-hydroxyethyl) hexadeanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300 3 (1996) 227-236
38. Nakae S., Suto H., Kakurai M., Sedgwick J.D., Tsai M., and Galli S.J. Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 6467-6472
39. Petrosino S., Karsak M., Cristino L., Gaffal E., Tütting T., Ueda N., Zimmer A., Bisogno T., and Di Marzo V. Protective role of palmitoylethanolamide in keratinocytes and its involvement in contact allergic dermatitis. 18th Annual Symposium on the Cannabinoids. International Cannabinoid Research Society, Burlington, Vermont (2008) 10
40. Petrosino S., Albanese F., Abramo F., and Di Marzo V. Increased skin levels of the aliamide palmitoylethanolamide and other endogenous fatty acid amides in dogs with atopic dermatitis. 33rd Annual WSAVA/FECAVA Congress. Dublin, Ireland (2008) 707
41. Pulvirenti N., Nasca M.R., and Micali G. Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study. Acta Dermatovenerol. Croat. 15 2 (2007) 80-83
42. Re G., Barbero R., Miolo A., and Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet. J. 173 (2007) 23-32
43. Ryberg E., Larsson N., Sjögren S., Hermansson N.-O., Leonova J., Elebrig T., Nilsson K., Drmota T., and Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152 (2007) 1092-1101
44. Samson M.T., Small-Howard A., Shimoda L.M., Koblan-Huberson M., Stokes A.J., and Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J. Immunol. 170 (2003) 4953-4962
45. 2 and its metabolites in leukocyte function. J. Leukoc. Biol. 81 (2007) 372-382
46. Scarampella F., Abramo F., and Noli C. Clinical and histological evaluation to an analogue of palmitoylethanolamide, PRL 120 (co micronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet. Dermatol. 12 1 (2001) 29-39
47. Showalter V.M., Compton D.R., Martin B.R., and Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278 (1996) 989-999
48. Stander S., Moormann C., Schumacher M., Buddenkotte J., Artuc M., Shpacovitch V., Brzoska T., Lippert U., Henz B.M., Luger T.A., Metze D., and Steinhoff M. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp. Dermatol. 13 (2004) 129-139
49. Stander S., Schmelz M., Metze D., Luger T., and Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J. Dermatol. Sci. 38 (2005) 177-188
50. Stempelj M., Bavec A., and Ferjan L. Regulation of nerve growth factor induced histamine and arachidonic acid release from rat mast cells by cannabinoids. Inflamm. Res. 55 Suppl. 1 (2006) S09-S10
51. Suto H., Nakae S., Kakurai M., Sedgwick J.D., Tsai M., and Galli S.J. Mast cell-associated TNF promotes dendritic cell migration. J. Immunol. 176 (2006) 4102-4112
52. von Ruedorffer U., Fisch R., Peel J., Roosje P., Griot-Wenk M., and Welle M. Flea bite hypersensitivity: new aspects on the involvement of mast cells. Vet. J. 165 (2003) 149-156
53. von Stebut E., Metz M., Milon G., Knop J., and Maurer M. Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1alpha/beta released from neutrophils recruited by mast cell-derived TNFalpha. Blood 101 (2003) 210-215
54. Wise L.E., Cannavacciulo R., Cravatt B.F., Marun B.F., and Lichtman A.H. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology 54 (2008) 181-188
55. Wuersch K., Brachelente C., Doherr M., Reist M., Sattler U., Forster U., Bertoni G., Peel J.E., and Welle M. Immune dysregulation in flea allergy dermatitis-a model for the immunopathogenesis of allergic dermatitis. Vet. Immunol. Immunopathol. 110 (2006) 311-323
56. Zuo Y., Perkins N.M., Tracey D.J., and Geczy C.L. Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. Pain 105 (2003) 467-479